B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes. 2021

Gihoon You, and Yangsoon Lee, and Yeon-Woo Kang, and Han Wook Park, and Kyeongsu Park, and Hyekang Kim, and Young-Min Kim, and Sora Kim, and Ji-Hae Kim, and Dain Moon, and Hyejin Chung, and Wonjun Son, and Ui-Jung Jung, and Eunyoung Park, and Shinai Lee, and Yong-Gyu Son, and Jaehyun Eom, and Jonghwa Won, and Yunji Park, and Jaeho Jung, and Seung-Woo Lee
Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea.

Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. Here, we developed a bispecific antibody (bsAb; B7-H3×4-1BB), targeting human B7-H3 (hB7-H3) and mouse or human 4-1BB, to restrict the 4-1BB stimulation in tumors. B7-H3×m4-1BB elicited a 4-1BB-dependent antitumor response in hB7-H3-overexpressing tumor models without systemic toxicity. BsAb primarily targets CD8 T cells in the tumor and increases their proliferation and cytokine production. Among the CD8 T cell population in the tumor, 4-1BB is solely expressed on PD-1+Tim-3+ "terminally differentiated" subset, and bsAb potentiates these cells for eliminating the tumor. Furthermore, the combination of bsAb and PD-1 blockade synergistically inhibits tumor growth accompanied by further increasing terminally differentiated CD8 T cells. B7-H3×h4-1BB also shows antitumor activity in h4-1BB-expressing mice. Our data suggest that B7-H3×4-1BB is an effective and safe therapeutic agent against B7-H3-positive cancers as monotherapy and combination therapy with PD-1 blockade.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016246 Lymphocytes, Tumor-Infiltrating Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer. Tumor Infiltrating Lymphocyte,Tumor-Derived Activated Cell,Tumor-Derived Activated Cells,Tumor-Infiltrating Lymphocyte,Tumor-Infiltrating Lymphocytes,Activated Cell, Tumor-Derived,Activated Cells, Tumor-Derived,Infiltrating Lymphocyte, Tumor,Infiltrating Lymphocytes, Tumor,Lymphocyte, Tumor Infiltrating,Lymphocyte, Tumor-Infiltrating,Lymphocytes, Tumor Infiltrating,Tumor Derived Activated Cell,Tumor Derived Activated Cells,Tumor Infiltrating Lymphocytes
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D061026 Programmed Cell Death 1 Receptor An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE. PD-1 Protein,Programmed Cell Death 1 Protein,Programmed Cell Death Protein 1,Antigens, CD279,CD279 Antigen,PD-1 Receptor,PD1 Receptor,Antigen, CD279,CD279 Antigens,PD 1 Protein,PD 1 Receptor,Receptor, PD-1,Receptor, PD1
D018033 Antibodies, Bispecific Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors. Bifunctional Antibodies,Bispecific Antibodies,Bispecific Monoclonal Antibodies,Antibodies, Bifunctional,Antibodies, Bispecific Monoclonal,Monoclonal Antibodies, Bispecific
D018414 CD8-Positive T-Lymphocytes A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes. Suppressor T-Lymphocytes, CD8-Positive,T8 Cells,T8 Lymphocytes,CD8-Positive Lymphocytes,Suppressor T-Cells, CD8-Positive,CD8 Positive Lymphocytes,CD8 Positive T Lymphocytes,CD8-Positive Lymphocyte,CD8-Positive Suppressor T-Cell,CD8-Positive Suppressor T-Cells,CD8-Positive Suppressor T-Lymphocyte,CD8-Positive Suppressor T-Lymphocytes,CD8-Positive T-Lymphocyte,Cell, T8,Cells, T8,Lymphocyte, CD8-Positive,Lymphocyte, T8,Lymphocytes, CD8-Positive,Lymphocytes, T8,Suppressor T Cells, CD8 Positive,Suppressor T Lymphocytes, CD8 Positive,Suppressor T-Cell, CD8-Positive,Suppressor T-Lymphocyte, CD8-Positive,T-Cell, CD8-Positive Suppressor,T-Cells, CD8-Positive Suppressor,T-Lymphocyte, CD8-Positive,T-Lymphocyte, CD8-Positive Suppressor,T-Lymphocytes, CD8-Positive,T-Lymphocytes, CD8-Positive Suppressor,T8 Cell,T8 Lymphocyte

Related Publications

Gihoon You, and Yangsoon Lee, and Yeon-Woo Kang, and Han Wook Park, and Kyeongsu Park, and Hyekang Kim, and Young-Min Kim, and Sora Kim, and Ji-Hae Kim, and Dain Moon, and Hyejin Chung, and Wonjun Son, and Ui-Jung Jung, and Eunyoung Park, and Shinai Lee, and Yong-Gyu Son, and Jaehyun Eom, and Jonghwa Won, and Yunji Park, and Jaeho Jung, and Seung-Woo Lee
January 2020, Frontiers in oncology,
Gihoon You, and Yangsoon Lee, and Yeon-Woo Kang, and Han Wook Park, and Kyeongsu Park, and Hyekang Kim, and Young-Min Kim, and Sora Kim, and Ji-Hae Kim, and Dain Moon, and Hyejin Chung, and Wonjun Son, and Ui-Jung Jung, and Eunyoung Park, and Shinai Lee, and Yong-Gyu Son, and Jaehyun Eom, and Jonghwa Won, and Yunji Park, and Jaeho Jung, and Seung-Woo Lee
February 2022, Oncology letters,
Gihoon You, and Yangsoon Lee, and Yeon-Woo Kang, and Han Wook Park, and Kyeongsu Park, and Hyekang Kim, and Young-Min Kim, and Sora Kim, and Ji-Hae Kim, and Dain Moon, and Hyejin Chung, and Wonjun Son, and Ui-Jung Jung, and Eunyoung Park, and Shinai Lee, and Yong-Gyu Son, and Jaehyun Eom, and Jonghwa Won, and Yunji Park, and Jaeho Jung, and Seung-Woo Lee
January 2023, American journal of cancer research,
Gihoon You, and Yangsoon Lee, and Yeon-Woo Kang, and Han Wook Park, and Kyeongsu Park, and Hyekang Kim, and Young-Min Kim, and Sora Kim, and Ji-Hae Kim, and Dain Moon, and Hyejin Chung, and Wonjun Son, and Ui-Jung Jung, and Eunyoung Park, and Shinai Lee, and Yong-Gyu Son, and Jaehyun Eom, and Jonghwa Won, and Yunji Park, and Jaeho Jung, and Seung-Woo Lee
July 2021, Journal for immunotherapy of cancer,
Gihoon You, and Yangsoon Lee, and Yeon-Woo Kang, and Han Wook Park, and Kyeongsu Park, and Hyekang Kim, and Young-Min Kim, and Sora Kim, and Ji-Hae Kim, and Dain Moon, and Hyejin Chung, and Wonjun Son, and Ui-Jung Jung, and Eunyoung Park, and Shinai Lee, and Yong-Gyu Son, and Jaehyun Eom, and Jonghwa Won, and Yunji Park, and Jaeho Jung, and Seung-Woo Lee
January 2021, Journal of hematology & oncology,
Gihoon You, and Yangsoon Lee, and Yeon-Woo Kang, and Han Wook Park, and Kyeongsu Park, and Hyekang Kim, and Young-Min Kim, and Sora Kim, and Ji-Hae Kim, and Dain Moon, and Hyejin Chung, and Wonjun Son, and Ui-Jung Jung, and Eunyoung Park, and Shinai Lee, and Yong-Gyu Son, and Jaehyun Eom, and Jonghwa Won, and Yunji Park, and Jaeho Jung, and Seung-Woo Lee
September 2003, Gene therapy,
Gihoon You, and Yangsoon Lee, and Yeon-Woo Kang, and Han Wook Park, and Kyeongsu Park, and Hyekang Kim, and Young-Min Kim, and Sora Kim, and Ji-Hae Kim, and Dain Moon, and Hyejin Chung, and Wonjun Son, and Ui-Jung Jung, and Eunyoung Park, and Shinai Lee, and Yong-Gyu Son, and Jaehyun Eom, and Jonghwa Won, and Yunji Park, and Jaeho Jung, and Seung-Woo Lee
January 2022, Life (Basel, Switzerland),
Gihoon You, and Yangsoon Lee, and Yeon-Woo Kang, and Han Wook Park, and Kyeongsu Park, and Hyekang Kim, and Young-Min Kim, and Sora Kim, and Ji-Hae Kim, and Dain Moon, and Hyejin Chung, and Wonjun Son, and Ui-Jung Jung, and Eunyoung Park, and Shinai Lee, and Yong-Gyu Son, and Jaehyun Eom, and Jonghwa Won, and Yunji Park, and Jaeho Jung, and Seung-Woo Lee
November 2023, Acta pharmacologica Sinica,
Gihoon You, and Yangsoon Lee, and Yeon-Woo Kang, and Han Wook Park, and Kyeongsu Park, and Hyekang Kim, and Young-Min Kim, and Sora Kim, and Ji-Hae Kim, and Dain Moon, and Hyejin Chung, and Wonjun Son, and Ui-Jung Jung, and Eunyoung Park, and Shinai Lee, and Yong-Gyu Son, and Jaehyun Eom, and Jonghwa Won, and Yunji Park, and Jaeho Jung, and Seung-Woo Lee
November 2020, Cancer immunology, immunotherapy : CII,
Gihoon You, and Yangsoon Lee, and Yeon-Woo Kang, and Han Wook Park, and Kyeongsu Park, and Hyekang Kim, and Young-Min Kim, and Sora Kim, and Ji-Hae Kim, and Dain Moon, and Hyejin Chung, and Wonjun Son, and Ui-Jung Jung, and Eunyoung Park, and Shinai Lee, and Yong-Gyu Son, and Jaehyun Eom, and Jonghwa Won, and Yunji Park, and Jaeho Jung, and Seung-Woo Lee
June 2016, Oncoimmunology,
Copied contents to your clipboard!